- Home
- NVVEW vs IDYA Comparison
NVVEW vs IDYA Comparison
Compare NVVEW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVEW
- IDYA
- Stock Information
- Founded
- NVVEW N/A
- IDYA 2015
- Country
- NVVEW China
- IDYA United States
- Employees
- NVVEW 12
- IDYA N/A
- Industry
- NVVEW Oil Refining/Marketing
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- NVVEW Energy
- IDYA Health Care
- Exchange
- NVVEW Nasdaq
- IDYA Nasdaq
- Market Cap
- NVVEW N/A
- IDYA 1.9B
- IPO Year
- NVVEW 2020
- IDYA 2019
- Fundamental
- Price
- NVVEW $0.02
- IDYA $21.12
- Analyst Decision
- NVVEW
- IDYA Strong Buy
- Analyst Count
- NVVEW 0
- IDYA 13
- Target Price
- NVVEW N/A
- IDYA $53.42
- AVG Volume (30 Days)
- NVVEW N/A
- IDYA 1.1M
- Earning Date
- NVVEW N/A
- IDYA 08-05-2025
- Dividend Yield
- NVVEW N/A
- IDYA N/A
- EPS Growth
- NVVEW N/A
- IDYA N/A
- EPS
- NVVEW N/A
- IDYA N/A
- Revenue
- NVVEW N/A
- IDYA $7,000,000.00
- Revenue This Year
- NVVEW N/A
- IDYA $101.20
- Revenue Next Year
- NVVEW N/A
- IDYA $286.70
- P/E Ratio
- NVVEW N/A
- IDYA N/A
- Revenue Growth
- NVVEW N/A
- IDYA N/A
- 52 Week Low
- NVVEW N/A
- IDYA $13.45
- 52 Week High
- NVVEW N/A
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- NVVEW N/A
- IDYA 50.44
- Support Level
- NVVEW N/A
- IDYA $21.08
- Resistance Level
- NVVEW N/A
- IDYA $22.86
- Average True Range (ATR)
- NVVEW 0.00
- IDYA 0.97
- MACD
- NVVEW 0.00
- IDYA -0.22
- Stochastic Oscillator
- NVVEW 0.00
- IDYA 25.51
About NVVEW Nuvve Holding Corp. Warrant
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.